Pharmacokinetics and pharmacodynamics of IFN-β1a in healthy volunteers

Journal of Interferon and Cytokine Research

Volumn 20, Issue 10, 2000, Pages 857-866

  Buchwalder, P A ^a   Buclin, T ^a   Trinchard, I ^b   Munafo, A ^b   Biollaz, J ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Serono International SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; BETA1A INTERFERON; NEOPTERIN; SYNTHETASE;

ADULT; ARTHRALGIA; ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; PHARMACODYNAMICS; PRIORITY JOURNAL; RETROBULBAR OPTIC NEUROPATHY; TINNITUS; VISUAL IMPAIRMENT;

ADOLESCENT; ADULT; AREA UNDER CURVE; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; INTERFERON TYPE I, RECOMBINANT; INTERFERON-BETA; MALE; MAXIMUM TOLERATED DOSE;

EID: 0033779037     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/10799900050163226     Document Type: Article

References (48)

1. Physiological mechanisms of production and action of interferons in response to viral infections
2. Sequence and structural homologies among type I and type II interferons
3. Placebo-controlled trial of topical interferon in labial and genital herpes
4. Ten years of experience with human fibroblast interferon in treatment of viral ophthalmic infections
5. Interferon and genital warts: Much potential, modest progress
6. Randomised double-blind trial of recombinant interferon-beta for condyloma acuminatum
7. Recombinant human interferon-beta for condylomata acuminata: A randomized, double-blind, placebo-controlled study of intralesional therapy
8. Recombinant human interferon-beta in the treatment of condylomata acuminata
9. Intramuscular natural beta interferon in the treatment of chronic hepatitis B: A multicentre trial
10. Predictors of sustained response, relapse and no response in patients with chronic hepatitis C treated with interferon-alpha
11. Beta-interferon therapy in patients with poor-prognosis Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). A phase II trial with preliminary evidence of antiviral activity and low incidence of opportunistic infections
12. Interferon-beta induced remission in a hairy cell leukemia patient resistant to interferon-alpha
13. Clinical effect of interferon in malignant brain tumours
14. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis
15. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis
16. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)
17. Magnetic resonance imaging changes with recombinant human interferon-beta-1a: A short-term study in relapsing-remitting multiple sclerosis
18. Interferon-beta-1b is effective in relapsing-remitting multiple sclerosis
19. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis
20. Interferon beta-1b in the treatment of multiple sclerosis
21. Effect of natural beta-interferon on cell proliferation and steroid receptor level in human breast cancer cells
22. Antiproliferative effect of interferons on human prostate carcinoma cell lines
23. Combination of beta-interferon and tamoxifen as a new way to overcome clinical resistance to tamoxifen in advanced breast cancer
24. Effects of interferon-beta on steroid receptors, prostaglandins and enzymatic activities in human endometrial cancer
25. Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity
26. Serum interferon level (2'-5') oligoadenylate synthetase activity in lymphocytes during clinical interferon application
27. Double-blind randomized phase I study on the clinical tolerance and biological effects of natural and recombinant interferon-β
28. Pharmacokinetics and pharmacodynamics of recombinant human interferon-β in healthy male volunteers
29. Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular subcutaneous administration
30. Interferons an overview of their pharmacology
31. Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta-1a (ITN-β1a) products administered intramuscularly in healthy male and female volunteers
32. Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-β
33. Biologic response (antiviral) to recombinant human interferon alpha 2a as a function of dose and route of administration in healthy volunteers
34. Double-blind randomized phase I study on the clinical tolerance and pharmacodynamics of natural and recombinant interferon-β given intravenously
35. Pharmacokinetics and pharmacodynamics of interferon beta-1a (IFN-β1a) in healthy volunteers after intravenous, subcutaneous, or intramuscular administration
36. Pharmacokinetics of recombinant human interferon-β(ser) in healthy volunteers and its effect on serum neopterin
37. Highly sensitive enzyme immunoassay of human interferon-β1
38. Determination of cytochrome p450 3A4/5 activity in vivo with dextromethorphan N-demethylation
39. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities
40. Pharmacodynamics of recombinant IFN-β during long-term treatment of malignant melanoma
41. The lymphatic route. V. Distribution of human natural interferon-β in rabbit plasma and lymph
42. Interferon β treatment for multiple sclerosis
43. Recombinant interferon-beta-1a: A review of its therapeutic efficacy in relapsing-remitting multiple sclerosis
44. Influence of interferon-β1a dose frequency on PBMC cytokine secretion and biological effect markers
45. Depression of drug metabolizing activity in the human liver by interferon-alpha
46. Depression of drug-metabolizing activity in the human liver by interferon-β
47. Prescribing recommendations for interferon-beta in multiple sclerosis